March 2008
Worldwide Biotech;Mar2008, Vol. 20 Issue 3, p4
Trade Publication
The article reports on the approval given by Ukraine's Ministry of Health to Generex Biotechnology Corporation for the conduct of a Phase III clinical trial for Generex Oral-lynâ„¢ at several clinical sites in the country. Generex has plans to conduct trials in seven countries. Type-1 diabetes mellitus patients are the target study participants of Generex. Particular focus is given to the primary objective of the study. Comments from Generex President and Chief Executive Officer (CEO) Anna Gluskin are included.


Related Articles

  • Generex Raising $20.7M Privately For Oral-lyn Insulin Spray Trials. Boggs, Jennifer // BioWorld Today;4/3/2008, Vol. 19 Issue 65, p3 

    This article reports on the money being raised by Generex Biotechnology Corp. to support the late-stage trials of Oral-lyn, an insulin spray product for Type I and Type II diabetes patients. Eight percent of convertible notes and warrants will be issued by Generex Biotechnology to existing...

  • life sciences In Brief.  // Chemical Market Reporter;3/21/2005, Vol. 267 Issue 12, p8 

    The article presents information on recent developments related to life sciences. Astralis Ltd. says that preliminary results from a Phase II study of its product candidate, a novel immuno-stimulatory product for psoriasis, did not meet its primary endpoint. Generex Biotechnology Corp. reports...

  • Generex Receives Patent for Buccal Delivery of Insulin.  // BioPharm International;Dec2006, Vol. 19 Issue 12, p12 

    The article reports on the acquisition of an Australian patent by Generex Biotechnology Corp. for its micellar system that delivers macromolecules through buccal lining. Excipients will form a spherical micelle of surfactant molecules which will shield the protein from digestion by buccal...

  • CLINIC ROUNDUP.  // BioWorld Today;5/11/2010, Vol. 21 Issue 90, p2 

    This section offers news briefs on clinical trials including the completion by Generex Biotechnology Corp. of enrollment of patients in its Phase III trial of Generex Oral-lyn and the encouraging pharmacokinetic results obtained by QRxPharma Inc. from its trial of a controlled-release dual-opioid.

  • Women CEOs Proving It: Glass Ceiling Can Break. Hollingsworth, Catherine // BioWorld Today;6/22/2009, Vol. 20 Issue 118, p1 

    The article offers insights from a number of women chief executive officers (CEO) about their successful careers in the biotechnology industry. Anna Gluskin of Generex Biotechnology cites some career highlights and admits to experiencing personal sacrifices such as a couple of divorces in her...

  • GENEREX ORAL INSULIN SPRAY APPROVED BY LEBANESE GOVERNMENT.  // Worldwide Biotech;Feb2009, Vol. 21 Issue 2, p1 

    The article reports that Lebanon's Ministry of Public Health has given its approval for Generex Biotechnology Corporation's Generex Oral-lyn proprietary oral insulin spray product, for importation, marketing, distribution, and commercial sale in the Republic of Lebanon. The oral insulin spray...

  • First in Bananas and Noninjectable Insulin. Trecroci, D. // Diabetes Health;Jul2005, Vol. 14 Issue 7, p16 

    Reports on the approval of noninjectable insulin formulation from Generex Biotechnology in Ecuador. Estimated number of people with diabetes in the country; Implication of the decision according to the company.

  • Generex wins approval for impaired glucose tolerance study.  // PharmaWatch: Biotechnology;Sep2008, Vol. 7 Issue 9, p13 

    The article reports that the ethics committee of the University Campus Bio-Medico of Rome has approved Generex Biotechnology Corp. to conduct a trial for its oral insulin spray Generex Oral-lyn in Italy. The trial aims to determine whether Generex Oral-lyn reduces the glucose levels of patients...

  • Accessible advice: Improving glucose control in patients with diabetes. Edwards, Alun // CMAJ: Canadian Medical Association Journal;10/19/99, Vol. 161 Issue 8, p975 

    Editorial. Comments on developments related to the improvement of glucose control in patients with diabetes. Impact of two clinical trials, the Diabetes Control and Complications Trial and the United Kingdom Prospective Diabetes Study; Changing approach of diabetes centers; Different models of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics